| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.54▼ | 1.54▼ | 1.51▲ | 1.33▲ | 1.34▲ |
| MA10 | 1.55▼ | 1.49▲ | 1.41▲ | 1.34▲ | 1.30▲ |
| MA20 | 1.55▼ | 1.39▲ | 1.33▲ | 1.31▲ | 1.22▲ |
| MA50 | 1.50▲ | 1.32▲ | 1.33▲ | 1.29▲ | 1.19▲ |
| MA100 | 1.39▲ | 1.33▲ | 1.34▲ | 1.21▲ | 1.80▼ |
| MA200 | 1.32▲ | 1.34▲ | 1.27▲ | 1.18▲ | 5.66▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | 0.017▲ | 0.032▲ | 0.006▲ | 0.028▲ |
| RSI | 46.608▼ | 74.294▲ | 74.680▲ | 66.650▲ | 60.272▲ |
| STOCH | 25.183 | 89.809▲ | 89.882▲ | 33.143 | 44.111 |
| WILL %R | -100.000▼ | -20.000▲ | -19.718▲ | -16.216▲ | -25.191 |
| CCI | -129.630▼ | 78.953 | 107.762▲ | 186.983▲ | 104.122▲ |
| ▲ PSAR&MOM | $FATE PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $FATE MACD cross and RSI above 55 | Set Alert |
| ▲ RSI&VOL | $FATE RSI Cross Up and Volume | Set Alert |
| RSI | $FATE RSI(14) Crossed Above 50 | Set Alert |
| ▲ MA | $FATE MA(20) Crossed Above MA(50) | Set Alert |
| ▲ MACD | $FATE MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| MA | $FATE Price Crossed Above MA(50) | Set Alert |
| MA | $FATE Price Crossed Above MA(26) | Set Alert |
| MA | $FATE Price Crossed Above MA(13) | Set Alert |
| MA | $FATE Price Crossed Above MA(7) | Set Alert |
| ▲ BREAK | $FATE Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $FATE Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $FATE Price Breaks 10 Days High | Set Alert |
|
Friday, May 01, 2026 01:05 PM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
|
|
Thursday, April 30, 2026 06:21 AM
Presentation Date / Time : Friday, May 1, 2026 / 2:55 p.m. to 6:00 p.m. EDT ...
|
|
Wednesday, April 15, 2026 10:15 PM
Fate Therapeutics (NASDAQ:FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing “off-the-shelf” CAR T-cell therapies, highlighting clinical progress in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/26 | 1.25 | 1.59 | 1.24 | 1.53 | 5,126,383 |
| 30/04/26 | 1.22 | 1.2799 | 1.22 | 1.25 | 743,109 |
| 29/04/26 | 1.28 | 1.298 | 1.22 | 1.24 | 912,025 |
| 28/04/26 | 1.30 | 1.34 | 1.28 | 1.30 | 738,728 |
| 27/04/26 | 1.36 | 1.38 | 1.30 | 1.31 | 1,358,462 |
| 24/04/26 | 1.32 | 1.345 | 1.29 | 1.33 | 960,902 |
| 23/04/26 | 1.37 | 1.39 | 1.30 | 1.32 | 990,830 |
| 22/04/26 | 1.39 | 1.399 | 1.36 | 1.37 | 702,521 |
| 21/04/26 | 1.40 | 1.40 | 1.32 | 1.35 | 1,215,299 |
| 20/04/26 | 1.38 | 1.41 | 1.35 | 1.39 | 1,334,517 |
|
|
||||
|
|
||||
|
|